NCT01999842 - Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine(s) GSK3206641A and GSK3206640A Administered in Adults 18 to 64 Years of Age | Biotech Hunter

Enrollment

424

Participants

Timeline

Start Date

November 25, 2013

Primary Completion Date

February 1, 2014

Study Completion Date

January 19, 2015

Conditions

Influenza

Interventions

BIOLOGICAL

Investigational H7N9 vaccine GSK3206641A

One dose of GSK3206641A H7N9 vaccine administered intramuscularly (IM) in the deltoid region of arm at Day 0 and the second dose of GSK3206641A H7N9 vaccine administered IM in the deltoid region of arm at Day 21

BIOLOGICAL

Investigational H7N9 vaccine GSK3206640A

One dose of GSK3206640A H7N9 vaccine administered IM at the deltoid region of arm at Day 0 and the second dose of GSK3206640A H7N9 vaccine administered IM at the deltoid region of arm at Day 21

BIOLOGICAL

Placebo

One dose of placebo administered IM at the deltoid region of arm at Day 0 and the second dose of placebo administered IM at the deltoid region of arm at Day 21

Trial Locations (8)

16506

GSK Investigational Site, Erie

30281

GSK Investigational Site, Stockbridge

32216

GSK Investigational Site, Jacksonville

83642

GSK Investigational Site, Boise

98105

GSK Investigational Site, Seattle

B2N 1L2

GSK Investigational Site, Truro

N4S 5P5

GSK Investigational Site, Woodstock

J1H 2G2

GSK Investigational Site, Sherbrooke